Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease

Thrombosis Research

Volumn 124, Issue 3, 2009, Pages 311-317

  Faraday, Nauder ^a   Yanek, Lisa R ^a   Vaidya, Dhananjay ^a   Kral, Brian ^a   Qayyum, Rehan ^a   Herrera Galeano, J Enrique ^a   Moy, Taryn F ^a   Becker, Diane M ^a   Becker, Lewis C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary disease; Leukocytes; Myocardial infarction; Platelets; Thrombosis

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; C REACTIVE PROTEIN; COLLAGEN; INTERLEUKIN 6;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FAMILY HISTORY; FEMALE; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPOIESIS; URINARY EXCRETION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CORONARY ARTERY DISEASE; CYTOKINES; DRUG TOLERANCE; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; PLATELET ACTIVATION;

EID: 67649742549     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.12.031     Document Type: Article

References (42)

1. Danesh J., Collins R., Appleby P., and Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 279 (1998) 1477-1482
2. Madjid M., Awan I., Willerson J.T., and Casscells S.W. Leukocyte count and coronary heart disease. J. Am. Coll. Cardiol. 44 (2004) 1945-1956
3. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336 14 (1997) 973-979
4. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G.A.R., Lowe G.D.O., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350 (2004) 1387-1397
5. Zairis M.N., Adamopoulou E.N., Manousakis S.J., Lyras A.G., Bibis G.P., Ampartzidou O.S., et al. Biomarkers of Inflammation and Outcome in Acute Coronary Syndromes (BIAS) Investigators. The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis 194 (2007) 397-402
6. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
7. Lindmark E., Diderholm E., Wallentin L., and Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 286 (2001) 2107-2113
8. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352 (2005) 1685-1695
9. Coller B.S. Leukocytosis and ischemic vascular disease morbidity and mortality: Is it time to intervene?. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 658-670
10. Fuster V., Badimon L., Badimon J.J., and Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). [Review]. N. Engl. J. Med. 326 4 (1992) 242-250
11. Pearson T.A., Blair S.N., Daniels S.R., Eckel R.H., Fair J.M., Fortmann S.P., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106 (2002) 388-391
12. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 324 (2002) 71-86
13. Fuster V., Dyken M.L., Vokonas P.S., and Hennekens C.H. Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group. Circulation 87 (1993) 659-675
14. Patrono C., Rodriguez L.A.G., Landolfi R., and Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353 (2005) 2373-2383
15. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
16. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. 41 (2003) 961-965
17. Grundmann K., Jaschonek K., Kleine B., Dichgans J., and Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J. Neurol. 250 (2003) 63-66
18. Ohmori T., Yatomi Y., Nonaka T., Kobayashi Y., Madoiwa S., Mimuro J., et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J. Thromb. Haemost. 4 (2006) 1271-1278
19. Snoep J.D., Hovens M.M.C., Eikenboom J.C.J., van der Bom J.G., and Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch. Intern. Med. 167 (2007) 1593-1599
20. McKee S.A., Sane D.C., and Deliargyris E.N. Aspirin resistance in cardiovascular disease: A review of prevalence, mechanisms, and clinical significance. Thromb. Haemost. 88 (2002) 711-715
21. Hankey G.J., and Eikelboom J.W. Aspirin resistance. Lancet 367 (2006) 606-617
22. Michelson A.D., Cattaneo M., Eikelboom J.W., Gurbel P., Kottke-Marchant K., Kunicki T.J., et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J. Thromb. Haemost. 3 (2005) 1309-1311
23. Faraday N., Yanek L.R., Mathias R., Herrera-Galeano J.E., Vaidya D., Moy T.F., et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation. 115 (2007) 2490-2496
24. Bath P.M., and Butterworth R.J. Platelet size: measurement, physiology and vascular disease. Blood Coagul. Fibrinolysis 7 2 (1996) 157-161
25. Martin J.F., Bath P.M.W., and Burr M.L. Influence of platelet size on outcome after myocardial infarction. Lancet 338 (1991) 1409-1411
26. Endler G., Klimesch A., Sunder-Plassmann H., Schillinger M., Exner M., Mannhalter C., et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br. J. Haematol. 117 (2002) 399-404
27. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Centers for Disease Control and Prevention, American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
28. Muller M.R., Salat A., Pulaki S., Stangl P., Ergun E., Schreiner W., et al. Influence of hematocrit and platelet count on impedance and reactivity of whole blood for electrical aggregometry. J. Pharmacol. Toxicol. Methods 34 (1995) 17-22
29. Ziegler S., Alt E., Brunner M., Speiser W., and Minar E. Influence of systemic inflammation on the interpretation of response to antiplatelet therapy, monitored by PFA-100. Semin. Thromb. Hemost. 31 (2005) 416-419
30. Sestito A., Sgueglia G.A., Spinelli A., Navarese E.P., Infusino F., Crea F., et al. Increased platelet reactivity in unstable angina patients is not related to C-reactive protein levels. Platelets 17 (2006) 336-339
31. Boncler M., Luzak B., Rozalski M., Golanski J., Rychlik B., and Watala C. Acetylsalicylic acid is compounding to antiplatelet effect of C-reactive protein. Thromb. Res. 119 (2007) 209-216
32. Markuszewski L., Rosiak M., Golanski J., Rysz J., Spychalska M., and Watala C. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?. Basic Clin. Pharmacol. Toxicol. 98 (2006) 503-509
33. Modica A.K.F., and Mooe T. Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J. Thromb. Haemost. 5 (2007) 507-511
34. Horne B.D., Anderson J.L., John J.M., Weaver A., Bair T.L., Jensen K.R., et al. Which white blood cell subtypes predict increased cardiovascular risk?. J. Am. Coll. Cardiol. 45 (2005) 1638-1643
35. Dragu R., Huri S., Zuckerman R., Suleiman M., Mutlak D., Agmon Y., et al. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. Atherosclerosis 196 (2008) 405-412
36. Maugeri N., Evangelista V., Piccardoni P., Dell'Elba G., Celardo A., de Gaetano G., et al. Transcellular metabolism of arachidonic acid: increased platelet thromboxane generation in the presence of activated polymorphonuclear leukocytes. Blood 80 (1992) 447-451
37. Faraday N., Scharpf R.B., Dodd-o J.M., Martinez E.A., Rosenfeld B.A., and Dorman T. Leukocytes can enhance platelet-mediated aggregation and thromboxane release via interaction of P-selectin glycoprotein ligand 1 with P-selectin. Anesthesiology 94 (2001) 145-151
38. Kirchhofer D., Riederer M.A., and Baumgartner H.R. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood 89 4 (1997) 1270-1278
39. Selak M.A., Chignard M., and Smith J.B. Cathepsin G is a strong platelet agonist released by neutrophils. Biochem. J. 251 (1988) 293-299
40. Renesto P., and Chignard M. Enhancement of cathepsin G-induced platelet activation by leukocyte elastase: consequence for the neutrophil-mediated platelet activation. Blood 82 (1993) 139-144
41. Pratico D., Iuliano L., Alessandri C., Camastra C., and Violi F. Polymorphonuclear leukocyte-derived O2-reactive species activate primed platelets in human whole blood. Am. J. Physiol. 264 (1993) H1582-H1587
42. Del Maschio A., Evangelista V., Rajtar G., Chen Z.M., Cerletti C., and De Gaetano G. Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents. Am. J. Physiol. 258 (1990) H870-H879